Jim Cramer had some pointed recommendations during CNBC's "Mad Money Lightning Round," weighing in on a handful of stocks that caught investor attention.
For Texas Instruments Incorporated (TXN), Cramer's advice was simple: hold. It's not exactly a ringing endorsement, but there's some backup for the call. Truist Securities analyst William Stein maintained a Hold rating on the chipmaker on Dec. 19 while bumping up the price target from $175 to $195. Sometimes patience is the play.
When asked about Crane Company (CR), Cramer kept it straightforward, calling it a "good" company. The industrial manufacturer has been making moves lately. On Jan. 5, Crane announced it wrapped up its acquisition of Precision Sensors & Instrumentation from Baker Hughes (BKR). The deal adds more instrumentation capabilities to Crane's portfolio, expanding its reach in industrial sensing technology.
But Cramer seemed most enthusiastic about Catalyst Pharmaceuticals, Inc. (CPRX). "It actually has, by the way, real earnings, and it's a very inexpensive stock. I think you've got a winner," he said. It's worth noting that Catalyst delivered on those earnings. Back on Nov. 5, the company reported third-quarter results that beat expectations across the board. Catalyst posted earnings of 68 cents per share, crushing the analyst consensus of 33 cents. Revenue came in at $148.392 million, topping the $136.802 million estimate. The company also raised its FY25 sales guidance above what Wall Street was expecting.
Price Action:
- Texas Instruments shares dipped 0.3% to close at $188.53 on Tuesday.
- Crane shares climbed 0.9% to finish at $204.73 on Tuesday.
- Catalyst Pharmaceuticals shares dropped 3.8% to settle at $22.35.
